Associations between diabetes-related genetic risk scores and residual beta cell function in type 1 diabetes: the GUTDM1 study.
CGM
Polygenic risk score
Residual beta cell function
Type 1 diabetes
Journal
Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777
Informations de publication
Date de publication:
26 Jun 2024
26 Jun 2024
Historique:
received:
12
01
2024
accepted:
29
04
2024
medline:
26
6
2024
pubmed:
26
6
2024
entrez:
26
6
2024
Statut:
aheadofprint
Résumé
Use of genetic risk scores (GRS) may help to distinguish between type 1 diabetes and type 2 diabetes, but less is known about whether GRS are associated with disease severity or progression after diagnosis. Therefore, we tested whether GRS are associated with residual beta cell function and glycaemic control in individuals with type 1 diabetes. Immunochip arrays and TOPMed were used to genotype a cross-sectional cohort (n=479, age 41.7 ± 14.9 years, duration of diabetes 16.0 years [IQR 6.0-29.0], HbA Higher GRS-1 and higher GRS-2 both showed a significant association with undetectable UCPCR (OR 0.78; 95% CI 0.69, 0.89 and OR 0.84: 95% CI 0.75, 0.93, respectively), which were attenuated after correction for sex and age of onset (GRS-2) and disease duration (GRS-1). Higher GRS-C2 was associated with detectable urinary C-peptide/creatinine ratio (≥0.01 nmol/mmol) after correction for sex and age of onset (OR 6.95; 95% CI 1.19, 40.75). A higher GRS-T2D was associated with less time below range (TBR) (OR for TBR<4% 1.41; 95% CI 1.01 to 1.96) and lower glucose coefficient of variance (β -1.53; 95% CI -2.76, -0.29). Diabetes-related GRS are associated with residual beta cell function in individuals with type 1 diabetes. These findings suggest some genetic contribution to preservation of beta cell function.
Identifiants
pubmed: 38922416
doi: 10.1007/s00125-024-06204-6
pii: 10.1007/s00125-024-06204-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Jan Dekker Stichting
ID : 2021T055
Organisme : ZonMw
ID : 09150172210019
Pays : Netherlands
Organisme : ZonMw
ID : 09150182010020
Pays : Netherlands
Organisme : Stichting Diabetes Onderzoek Nederland
ID : 2020.10.002
Informations de copyright
© 2024. The Author(s).
Références
Ilonen J, Lempainen J, Veijola R (2019) The heterogeneous pathogenesis of type 1 diabetes mellitus. Nat Rev Endocrinol 15(11):635–650. https://doi.org/10.1038/s41574-019-0254-y
doi: 10.1038/s41574-019-0254-y
pubmed: 31534209
Gillespie KM, Bain SC, Barnett AH, Bingley PJ, Christie MR, Gill GV, Gale EA (2004) The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. Lancet 364(9446):1699–1700. https://doi.org/10.1016/s0140-6736(04)17357-1
doi: 10.1016/s0140-6736(04)17357-1
pubmed: 15530631
Hermann R, Knip M, Veijola R et al (2003) Temporal changes in the frequencies of HLA genotypes in patients with type 1 diabetes – indication of an increased environmental pressure? Diabetologia 46(3):420–425. https://doi.org/10.1007/s00125-003-1045-4
doi: 10.1007/s00125-003-1045-4
pubmed: 12687342
Vehik K, Hamman RF, Lezotte D, Norris JM, Klingensmith GJ, Rewers M, Dabelea D (2008) Trends in high-risk HLA susceptibility genes among Colorado youth with type 1 diabetes. Diabetes Care 31(7):1392–1396. https://doi.org/10.2337/dc07-2210
doi: 10.2337/dc07-2210
pubmed: 18356404
pmcid: 2453682
Vatanen T, Franzosa EA, Schwager R et al (2018) The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. Nature 562(7728):589–594. https://doi.org/10.1038/s41586-018-0620-2
doi: 10.1038/s41586-018-0620-2
pubmed: 30356183
pmcid: 6296767
Budoff M, Backlund JC, Bluemke DA et al (2019) The association of coronary artery calcification with subsequent incidence of cardiovascular disease in type 1 diabetes: the DCCT/EDIC trials. JACC Cardiovasc Imaging 12(7 Pt 2):1341–1349. https://doi.org/10.1016/j.jcmg.2019.01.014
doi: 10.1016/j.jcmg.2019.01.014
pubmed: 30878435
pmcid: 6612565
Jacobson AM, Braffett BH, Cleary PA, Gubitosi-Klug RA, Larkin ME, Group tDER (2013) The long-term effects of type 1 diabetes treatment and complications on health-related quality of life: a 23-year follow-up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort. Diabetes Care 36(10):3131–3138. https://doi.org/10.2337/dc12-2109
doi: 10.2337/dc12-2109
pubmed: 23835693
pmcid: 3781542
Barr EL, Zimmet PZ, Welborn TA et al (2007) Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 116(2):151–157. https://doi.org/10.1161/circulationaha.106.685628
doi: 10.1161/circulationaha.106.685628
pubmed: 17576864
Harjutsalo V, PongracBarlovic D, Groop P-H (2021) Long-term population-based trends in the incidence of cardiovascular disease in individuals with type 1 diabetes from Finland: a retrospective, nationwide, cohort study. Lancet Diabetes Endocrinol 9(9):575–585. https://doi.org/10.1016/S2213-8587(21)00172-8
doi: 10.1016/S2213-8587(21)00172-8
pubmed: 34303414
Lin K, Yang X, Wu Y, Chen S, Zeng Q (2021) Residual β-cell function in type 1 diabetes followed for 2 years after 3C study. J Diabetes Res 2021:9946874. https://doi.org/10.1155/2021/9946874
doi: 10.1155/2021/9946874
pubmed: 34258294
pmcid: 8261175
Oram RA, McDonald TJ, Shields BM et al (2014) Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors. Diabetes Care 38(2):323–328. https://doi.org/10.2337/dc14-0871
doi: 10.2337/dc14-0871
pubmed: 25519449
FuhriSnethlage CM, McDonald TJ, Oram RD et al (2023) Residual β-cell function is associated with longer time in range in individuals with type 1 diabetes. Diabetes Care. https://doi.org/10.2337/dc23-0776
doi: 10.2337/dc23-0776
Sørensen JS, Johannesen J, Pociot F et al (2013) Residual β-cell function 3–6 years after onset of type 1 diabetes reduces risk of severe hypoglycemia in children and adolescents. Diabetes Care 36(11):3454–3459. https://doi.org/10.2337/dc13-0418
doi: 10.2337/dc13-0418
pubmed: 23990516
pmcid: 3816898
Steffes MW, Sibley S, Jackson M, Thomas W (2003) β-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care 26(3):832–836. https://doi.org/10.2337/diacare.26.3.832
doi: 10.2337/diacare.26.3.832
pubmed: 12610045
Forlenza GP, McVean J, Beck RW et al (2023) Effect of verapamil on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: a randomized clinical trial. JAMA 329(12):990–999. https://doi.org/10.1001/jama.2023.2064
doi: 10.1001/jama.2023.2064
pubmed: 36826844
pmcid: 9960020
Krogvold L, Mynarek IM, Ponzi E et al (2023) Pleconaril and ribavirin in new-onset type 1 diabetes: a phase 2 randomized trial. Nat Med 29:2902–2908. https://doi.org/10.1038/s41591-023-02576-1
doi: 10.1038/s41591-023-02576-1
pubmed: 37789144
pmcid: 10667091
de Groot P, Nikolic T, Pellegrini S et al (2021) Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial. Gut 70(1):92–105. https://doi.org/10.1136/gutjnl-2020-322630
doi: 10.1136/gutjnl-2020-322630
pubmed: 33106354
Redondo MJ, Jeffrey J, Fain PR, Eisenbarth GS, Orban T (2008) Concordance for islet autoimmunity among monozygotic twins. N Engl J Med 359(26):2849–2850. https://doi.org/10.1056/NEJMc0805398
doi: 10.1056/NEJMc0805398
pubmed: 19109586
Chiou J, Geusz RJ, Okino M-L et al (2021) Interpreting type 1 diabetes risk with genetics and single-cell epigenomics. Nature 594(7863):398–402. https://doi.org/10.1038/s41586-021-03552-w
doi: 10.1038/s41586-021-03552-w
pubmed: 34012112
pmcid: 10560508
Harsunen M, Haukka J, Harjutsalo V et al (2023) Residual insulin secretion in individuals with type 1 diabetes in Finland: longitudinal and cross-sectional analyses. Lancet Diabetes Endocrinol 11(7):465–473. https://doi.org/10.1016/S2213-8587(23)00123-7
doi: 10.1016/S2213-8587(23)00123-7
pubmed: 37290465
McKeigue PM, Spiliopoulou A, McGurnaghan S et al (2019) Persistent C-peptide secretion in type 1 diabetes and its relationship to the genetic architecture of diabetes. BMC Med 17(1):165. https://doi.org/10.1186/s12916-019-1392-8
doi: 10.1186/s12916-019-1392-8
pubmed: 31438962
pmcid: 6706940
Roshandel D, Gubitosi-Klug R, Bull SB et al (2018) Meta-genome-wide association studies identify a locus on chromosome 1 and multiple variants in the MHC region for serum C-peptide in type 1 diabetes. Diabetologia 61(5):1098–1111. https://doi.org/10.1007/s00125-018-4555-9
doi: 10.1007/s00125-018-4555-9
pubmed: 29404672
pmcid: 5876265
Sharp SA, Rich SS, Wood AR et al (2019) Development and standardization of an improved type 1 diabetes genetic risk score for use in newborn screening and incident diagnosis. Diabetes Care 42(2):200–207. https://doi.org/10.2337/dc18-1785
doi: 10.2337/dc18-1785
pubmed: 30655379
pmcid: 6341291
Oram RA, Sharp SA, Pihoker C et al (2022) Utility of diabetes type-specific genetic risk scores for the classification of diabetes type among multiethnic youth. Diabetes Care 45(5):1124–1131. https://doi.org/10.2337/dc20-2872
doi: 10.2337/dc20-2872
pubmed: 35312757
pmcid: 9174964
Patel KA, Oram RA, Flanagan SE et al (2016) Type 1 diabetes genetic risk score: a novel tool to discriminate monogenic and type 1 diabetes. Diabetes 65(7):2094–2099. https://doi.org/10.2337/db15-1690
doi: 10.2337/db15-1690
pubmed: 27207547
Holt RIG, DeVries JH, Hess-Fischl A et al (2021) The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 64(12):2609–2652. https://doi.org/10.1007/s00125-021-05568-3
doi: 10.1007/s00125-021-05568-3
pubmed: 34590174
pmcid: 8481000
ElSayed NA, Aleppo G, Aroda VR et al (2022) 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes—2023. Diabetes Care 46(Suppl. 1):S19–S40. https://doi.org/10.2337/dc23-S002
doi: 10.2337/dc23-S002
pmcid: 9810477
McDonald TJ, Knight BA, Shields BM, Bowman P, Salzmann MB, Hattersley AT (2009) Stability and reproducibility of a single-sample urinary C-peptide/creatinine ratio and its correlation with 24-h urinary C-peptide. Clin Chem 55(11):2035–2039. https://doi.org/10.1373/clinchem.2009.129312
doi: 10.1373/clinchem.2009.129312
pubmed: 19713273
Besser RE, Ludvigsson J, Jones AG, McDonald TJ, Shields BM, Knight BA, Hattersley AT (2011) Urine C-peptide creatinine ratio is a noninvasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes. Diabetes Care 34(3):607–609. https://doi.org/10.2337/dc10-2114
doi: 10.2337/dc10-2114
pubmed: 21285386
pmcid: 3041191
Battelino T, Danne T, Bergenstal RM et al (2019) Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range. Diabetes Care 42(8):1593–1603. https://doi.org/10.2337/dci19-0028
doi: 10.2337/dci19-0028
pubmed: 31177185
pmcid: 6973648
Rayner N, McCarthy M (2011) Development and use of a pipeline to generate strand and position information for common genotyping chips. Presented at the Annual Meeting of the American Society of Human Genetics, Montreal, Canada. Available from https://www.chg.ox.ac.uk/~wrayner/tools/WR-ASHG2011posterPP-portrait.pdf
Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen WM (2010) Robust relationship inference in genome-wide association studies. Bioinformatics 26(22):2867–2873. https://doi.org/10.1093/bioinformatics/btq559
doi: 10.1093/bioinformatics/btq559
pubmed: 20926424
pmcid: 3025716
Das S, Forer L, Schönherr S et al (2016) Next-generation genotype imputation service and methods. Nat Genet 48(10):1284–1287. https://doi.org/10.1038/ng.3656
doi: 10.1038/ng.3656
pubmed: 27571263
pmcid: 5157836
Oram RA, Patel K, Hill A et al (2016) A type 1 diabetes genetic risk score can aid discrimination between type 1 and type 2 diabetes in young adults. Diabetes Care 39(3):337–344. https://doi.org/10.2337/dc15-1111
doi: 10.2337/dc15-1111
pubmed: 26577414
Machiela MJ, Chanock SJ (2015) LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics 31(21):3555–3557. https://doi.org/10.1093/bioinformatics/btv402
doi: 10.1093/bioinformatics/btv402
pubmed: 26139635
pmcid: 4626747
Shields BM, McDonald TJ, Oram R et al (2018) C-peptide decline in type 1 diabetes has two phases: an initial exponential fall and a subsequent stable phase. Diabetes Care 41(7):1486–1492. https://doi.org/10.2337/dc18-0465
doi: 10.2337/dc18-0465
pubmed: 29880650
Williams MD, Bacher R, Perry DJ et al (2021) Genetic composition and autoantibody titers model the probability of detecting C-peptide following type 1 diabetes diagnosis. Diabetes 70(4):932–943. https://doi.org/10.2337/db20-0937
doi: 10.2337/db20-0937
pubmed: 33419759
pmcid: 7980194
Onengut-Gumuscu S, Chen W-M, Burren O et al (2015) Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers. Nat Genet 47(4):381–386. https://doi.org/10.1038/ng.3245
doi: 10.1038/ng.3245
pubmed: 25751624
pmcid: 4380767
Galicia-Garcia U, Benito-Vicente A, Jebari S et al (2020) Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci 21(17):6275. https://doi.org/10.3390/ijms21176275
doi: 10.3390/ijms21176275
pubmed: 32872570
pmcid: 7503727